Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study

Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study

Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking. Objectives: To compare pembrolizumab versus...

Full description

Bibliographic Details
Main Authors: Yu Du, Zhonghui Qi, Xianbin Liang, Jie Dai, Xiaoting Wei, Xue Bai, Lili Mao, Zhihong Chi, Chuanliang Cui, Bin Lian, Bixia Tang, Xuan Wang, Yu Chen, Jun Guo, Lu Si
Format: Article
Language:English
Published: Mattioli1885 2024-01-01
Series:Dermatology Practical & Conceptual
Subjects:
PD-1
Interferon
Children
Adolescents
Melanoma
Online Access:https://dpcj.org/index.php/dpc/article/view/3517

Internet

https://dpcj.org/index.php/dpc/article/view/3517

Similar Items